oasis 1 trial oral semaglutide 50 mg obesity nejm 2023 oasis-1 Higher-dose oral semaglutide may be beneficial option for type 2 diabetes, obesity Semaglutide and Cardiovascular Outcomes in – oasis-1 oral semaglutide 50 mg

This is the highest percentage weight loss ever recorded in a trial for an obesity drug

vessel type (power boats, sailboats, cruise ships, others)

GLP-1 for Healthy Weight Loss GLP-1 (glucagon-like peptide-1 receptor agonists) medications are injectable treatments that mimic a natural hormone in the body to support weight loss

20% higher D30 engagement from new features launched September 22, 2025 is based on a pre-post analysis from August 22 to October 24, 2025 of D30 engagement in key in-app behaviours (completing any Home Screen Task, tapping the Bank button to bank rewards for steps, viewing the Health Report, logging medication, or reading an article)

However, it is not a replacement for insulin, particularly in type 1 diabetes, as it does not perform the vital functions of insulin in glucose metabolism

Mazidi, M